Seres Therapeutics (MCRB) Inventory (2023 - 2024)
Seres Therapeutics' (MCRB) quarterly Inventory came in at $53.0 million in Q2 2024, up 892.45% year-over-year from $5.3 million in Q3 2023, and up 26.26% quarter-over-quarter from $42.0 million in Q1 2024.
Analysis
Seres Therapeutics (MCRB) Inventory (2023 - 2024) Analysis & Trends
Seres Therapeutics has disclosed Inventory across 2 years of filings, most recently posting $53.0 million for Q2 2024.
- In Q2 2024, Inventory rose 892.45% year-over-year to $53.0 million; the TTM figure through Jun 2024 stood at $53.0 million (up 892.45% YoY), while the FY2023 annual figure was $29.6 million, changed N/A from the prior year.
- Inventory came in at $53.0 million for Q2 2024 at Seres Therapeutics, up from $42.0 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $53.0 million in Q2 2024 to a low of $5.3 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 6.22 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.95 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 3.08 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 371.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 280.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 97.11 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.38 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Seres Therapeutics | 49.89 Mn | 49.89 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 53.00 Mn |
| Mar 31, 2024 | 41.97 Mn |
| Dec 31, 2023 | 29.65 Mn |
| Sep 30, 2023 | 18.53 Mn |
| Jun 30, 2023 | 5.34 Mn |